A device smaller than a quarter is giving heart patients a new lease on life. The Watchman device is implanted in the heart to prevent blood clots from forming without the need of blood thinners. This ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...

Apr. 9—Medical Center Hospital is proud to announce that Dr. Manohar Angirekula, Dr. Adam Farber and Dr. Fernando Boccalandro successfully implanted the first WATCHMAN FLX Pro Device on April 1. MCH ...

The Cottage Heart & Vascular Center’s structural heart team at Santa Barbara Cottage Hospital (SBCH) recently performed their 1,000th WATCHMAN device procedure, a minimally invasive solution for ...

DEAR DR. ROACH: I am a 70-year old woman with a prior history of asymptomatic atrial fibrillation (AFib). I’ve been in normal sinus rhythm since having two catheter ablations in 2018. I take Eliquis ...

CORPUS CHRISTI, Texas — The watchman device is a left atrial appendage occlusion device that allows people in atrial fibrillation to stop anticoagulants; medicines that not everybody can tolerate.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Rates of patency and device-related thrombus were ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: I am a 70-year old woman with a prior history of ...

MedStar Heart & Vascular Institute now offers patients with irregular heart rhythm a minimally invasive option to reduce the risk of stroke, as well as enable stopping long-term use of blood thinning ...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

On Saturday, Boston Scientific Corporation (NYSE:BSX) unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device ...

The WATCHMAN FLX Pro team (pictured here) has successfully completed 159 WATCHMAN procedures, and will now only use the updated WATCHMAN FLX Pro Device moving forward. (Courtesy Photo) Medical Center ...